2006 FDA Approved Drugs

The following database contains a listing of drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Drug information typically includes the drug name, approval status, indication of use, and clinical trial results. Review descriptions for our medical therapeutic area list to help assist in your search.

Join our Drug Research Updates group on LinkedIn! 
Find out more about the types of drugs included in this listing.

Cardiology/Vascular Diseases

Ranexa (ranolazine); CV Therapeutics; For the treatment of chronic angina in patients failing first-line therapy, Approved January 2006

Dermatology

Desonate (desonide); Dow Pharm; For the treatment of atopic dermatitis, Approved October 2006

Verdeso (desonide); Connetics Corporation; For the treatment of atopic dermatitis, Approved September 2006

Endocrinology

Elestrin (estradiol gel); BioSante; For the treatment of vasomotor symptoms associated with menopause, Approved December 2006

Januvia (sitagliptin phosphate); Merck; For the treatment of type II diabetes, Approved October 2006

Family Medicine

Desonate (desonide); Dow Pharm; For the treatment of atopic dermatitis, Approved October 2006

Elestrin (estradiol gel); BioSante; For the treatment of vasomotor symptoms associated with menopause, Approved December 2006

Eraxis (anidulafungin); Pfizer; For the treatment of Candida fungal infections, Approved February 2006

Januvia (sitagliptin phosphate); Merck; For the treatment of type II diabetes, Approved October 2006

Noxafil (posaconazole); Schering-Plough; For the treatment of fungal infections, Approved in September 2006

Prezista (darunavir); Tibotec; For the treatment of treatment-resistant HIV infections, Approved June 2006

Ranexa (ranolazine); CV Therapeutics; For the treatment of chronic angina in patients failing first-line therapy, Approved January 2006

Vectibix (panitumumab); Amgen; For the treatment of colorectal cancer, Approved September 2006

Verdeso (desonide); Connetics Corporation; For the treatment of atopic dermatitis, Approved September 2006

Vivitrol (naltrexone for extended-release injectable suspension); Alkermes; For the treatment of alcohol dependence, Approved April 2006

Gastroenterology

Amitiza (lubiprostone); Sucampo/Takeda; For the treatment of chronic idiopathic constipation, Approved January 2006

Hematology

Dacogen (decitabine); MGI Pharma; For the treatment of both treatment-naïve and -experienced Myelodysplastic Syndromes, Approved May 2006

Hepatology (Liver, Pancreatic, Gall Bladder)

Tyzeka (telbivudine); Idenix Pharma; For the treatment of hepatitis B virus, Approved October 2006

Immunology

Eraxis (anidulafungin); Pfizer; For the treatment of Candida fungal infections, Approved February 2006

Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine); Merck; For the prevention of cervical cancer associated with human papillomavirus, Approved June 2006

Noxafil (posaconazole); Schering-Plough; For the treatment of fungal infections, Approved in September 2006

Prezista (darunavir); Tibotec; For the treatment of treatment-resistant HIV infections, Approved June 2006

Rotateq (rotavirus vaccine, live oral pentavalent); Merck; For the prevention of gastroenteritis associated with rotavirus infections in infants, Approved February 2006

Tyzeka (telbivudine); Idenix Pharma; For the treatment of hepatitis B virus, Approved October 2006

Veregen (kunecatechins); Medigene; For the treatment of external genital and perianal warts, Approved October 2006

Infections and Infectious Diseases

Eraxis (anidulafungin); Pfizer; For the treatment of Candida fungal infections, Approved February 2006

Noxafil (posaconazole); Schering-Plough; For the treatment of fungal infections, Approved in September 2006

Prezista (darunavir); Tibotec; For the treatment of treatment-resistant HIV infections, Approved June 2006

Tyzeka (telbivudine); Idenix Pharma; For the treatment of hepatitis B virus, Approved October 2006

Veregen (kunecatechins); Medigene; For the treatment of external genital and perianal warts, Approved October 2006

Neurology

Invega (paliperidone); Janssen Pharmaceuticals; For the treatment of schizophrenia, Approved December 2006

Vivitrol (naltrexone for extended-release injectable suspension); Alkermes; For the treatment of alcohol dependence, Approved April 2006

Obstetrics/Gynecology (Women’s Health)

Elestrin (estradiol gel); BioSante; For the treatment of vasomotor symptoms associated with menopause, Approved December 2006

Oncology

Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine); Merck; For the prevention of cervical cancer associated with human papillomavirus, Approved June 2006

Sprycel (dasatinib); Bristol-Myers Squibb; For the treatment of imatinib-resistant chronic myeloid leukemia, Approved June 2006

Sutent (sunitinib); Pfizer; For the treatment of kidney cancer and gastrointestinal stromal tumors, Approved January 2006

Vectibix (panitumumab); Amgen; For the treatment of colorectal cancer, Approved September 2006

Ophthalmology

Lucentis (ranibizumab); Genentech; For the treatment of neovascular (wet) age related macular degeneration, Approved June 2006

Pediatrics/Neonatology

Desonate (desonide); Dow Pharm; For the treatment of atopic dermatitis, Approved October 2006

Elaprase (idursulfase); Shire Pharmaceuticals; For the treatmenr of mucopolysaccharidosis II (Hunter Syndrome), Approved July 2006

Myozyme (alglucosidase alfa); Genzyme; For the treatment of Pompe disease (glycogen storage disease type II), Approved April 2006

Podiatry

Veregen (kunecatechins); Medigene; For the treatment of external genital and perianal warts, Approved October 2006

Psychiatry/Psychology

Chantix (varenicline); Pfizer; For the treatment of nicotine addiction, Approved May 2006

Invega (paliperidone); Janssen Pharmaceuticals; For the treatment of schizophrenia, Approved December 2006

Vivitrol (naltrexone for extended-release injectable suspension); Alkermes; For the treatment of alcohol dependence, Approved April 2006

Pulmonary/Respiratory Diseases

Brovana (arformoterol tartrate); Sepracor; For the treatment of Chronic Obstructive Pulmonary Disease, Approved in October 2006

Rheumatology

Elaprase (idursulfase); Shire Pharmaceuticals; For the treatmenr of mucopolysaccharidosis II (Hunter Syndrome), Approved July 2006